02561.HK
VISEN Pharmaceuticals
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 13.93
−0.50%Year over year
Reported trailing growth
- Revenue
- +1227.9%
- EBITDA
- -13.9%
- EBIT
- -16.4%
- EPS
- +1.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -94.2%
- EBITDA
- -33.2%
- EBIT
- -34.1%
- Net income
- -35.5%
- EPS
- -22.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026